ELF3 and neoplasm: ELF3, an m6A “reader” with cancer-specific expression/mutation patterns (Figure 1A–C and Figure S2A,B), demonstrates drug sensitivity correlations (Figure 5A and Figure S10), suggesting dual roles in the therapeutic response and tumor progression.